Skip to content

Viking Therapeutics VKTX Book value per share

Book value per share at other companies

Eli Lilly logo
Eli LillyLLY
$34.82+98.9%
Pfizer logo
PfizerPFE
$15.72-0.6%
Amgen logo
AmgenAMGN
$16.89+47.2%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$18.72-26.0%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$12.30-8.7%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$31.43+6.6%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.53B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's book value per share?
Viking Therapeutics (VKTX) reported book value per share of $4.34 in Q1 2026.
How has Viking Therapeutics's book value per share changed year-over-year?
Viking Therapeutics's book value per share decreased by 42.5% year-over-year, from $7.56 to $4.34.
What is the long-term trend for Viking Therapeutics's book value per share?
Over 5 years (2020 to 2025), Viking Therapeutics's book value per share has grown at a 11.0% compound annual growth rate (CAGR), from $3.37 to $5.67.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.